New Baxalta drug emerges in Pfizer-monopolizing hemophilia B market
In the domestic hemophilia B(congenital factor ix deficiency) market which had been monopolized by Pfizer with Benefix, a rival emerged.
Recently, the Ministry of Health and Welfare(MOHW) administratively notified the ‘Amendment Announcement to Details on Application Standards and Methods of In...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
